Income statement
USD
Annual
| Metric | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 4M | 1M | 669K |
| Gross Profit | 0 | 0 | 1M | 647K | 473K |
| Operating Income | 10M | 5M | 13M | 4M | 2M |
| EBITDA | -7M | -5M | -10M | -4M | -2M |
| Net Income | -11M | -8M | -13M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.003
+0.00% today
Window Change
+0.00%
Window
May 28, 2026 → Jun 18, 2026
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 16 bars · May 28, 2026 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
VioQuest Pharmaceuticals, Inc. (VOQP) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (May 28, 2026 → Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -12.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -12.0%, free cash flow -9.3% with operating margin 0.0% and ROIC -613.1%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines VOQP price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
VOQP
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
VOQP Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for VOQP and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$669.0K
-55.0% YoY
FY Net Income
-$2.0M
+49.8% YoY
Free Cash Flow
-$1.9M
+54.8% YoY
Revenue Growth
+0.0%
EPS Growth
-12.0%
Gross Margin
0.0%
Net Margin
0.0%
Income statement
USD
| Metric | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 4M | 1M | 669K |
| Gross Profit | 0 | 0 | 1M | 647K | 473K |
| Operating Income | 10M | 5M | 13M | 4M | 2M |
| EBITDA | -7M | -5M | -10M | -4M | -2M |
| Net Income | -11M | -8M | -13M | -4M | -2M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2007 | 2006 | 2005 | 2004 | 2003 |
|---|---|---|---|---|---|
| Cash & Equivalents | 695K | 3M | 6M | 3M | 659K |
| Total Assets | 1M | 6M | 8M | 5M | 2M |
| Total Liabilities | 6M | 3M | 2M | 1M | 761K |
| Shareholder Equity | -4M | 3M | 6M | 4M | 825K |
| Total Debt | 3M | 265K | 265K | 0 | 0 |
| Net Debt | 2M | -3M | -6M | -3M | -659K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
2M
+56.8% YoY
Capital Expenditures
237K
+33.5% YoY
Free Cash Flow
2M
+54.8% YoY
Key ratios
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
1325.4%
Debt / Equity
-0.65x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.